SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
Rhea-AI Summary
Sera Prognostics (Nasdaq: SERA) reported first quarter 2026 results and key commercial and clinical milestones on May 6, 2026. Highlights include publication of the randomized PRIME trial showing reduced early preterm births (−56% <32 weeks; −32% <35 weeks), NICU admissions (−20%), and neonatal morbidity (−20%). The company launched a third partnership to reach >350 providers, is in active talks with 13 payers across 15 states, and is preparing a CE marking dossier for mid‑year submission. Q1 revenue was $14,000, net loss was $8.4 million, and cash and securities totaled $86.8 million, with a cash runway extended through 2029.
Positive
- PRIME trial randomized success: reduced early preterm births −56% (<32w) and −32% (<35w)
- Clinical outcomes improvement: NICU admissions −20% and neonatal morbidity −20%
- Commercial expansion: third partnership program reaching over 350 providers
- Cash runway extended through 2029 with ~$86.8M in cash and securities
- Payer engagement: active discussions with 13 payers across 15 states
Negative
- Revenue decline: Q1 2026 revenue $14,000 versus $38,000 in Q1 2025 (≈63% decrease)
- Net loss: Q1 2026 net loss of $8.4M continues operating deficits
Market Reaction – SERA
Following this news, SERA has declined 4.97%, reflecting a moderate negative market reaction. Our momentum scanner has triggered 5 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $1.72. This price movement has removed approximately $4M from the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner flagged SERA moving up while only one peer, PROF, also showed upside momentum. Broader peers show a mix of gains and losses, pointing to stock-specific dynamics rather than a coordinated sector move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | FY25 earnings | Positive | -6.3% | Reported FY25 results, PRIME data impact, and cash runway into 2028. |
| Nov 13 | Q3 2025 earnings | Positive | +0.3% | Q3 2025 results with early commercial progress and strong cash position. |
| Aug 06 | Q2 2025 earnings | Positive | -5.5% | Q2 2025 financials showing modest revenue, lower R&D, and ample cash. |
| May 07 | Q1 2025 earnings | Positive | -11.7% | Q1 2025 results highlighting PRIME data and growing payer engagement. |
| Mar 19 | FY24 earnings | Positive | -5.1% | Q4 and 2024 results with PRIME outcomes and strengthened balance sheet. |
Earnings releases have typically been followed by negative price reactions despite highlighting progress on PRIME data, commercialization, and cash runway, with an average move of -5.63% on prior earnings announcements.
Over the past year, Sera’s earnings reports have emphasized PRIME trial achievements, gradual commercialization of the PreTRM test, and a solid cash position extending into 2028. Yet shares often traded lower following these updates, including the Q4 2025 report and multiple 2025 quarters. Today’s Q1 2026 release continues themes of modest revenue ($14,000), controlled R&D spend, and a cash balance of about $86.8M funding operations through 2029, extending the company’s runway versus prior reports.
Historical Comparison
Earnings releases for SERA have averaged a -5.63% move, often skewing negative despite updates on PRIME data, commercialization steps, and extended cash runway, framing expectations for how similar news has traded historically.
Across recent earnings, Sera has evolved from primarily clinical validation toward commercialization of PreTRM, repeatedly underscoring PRIME study results, payer engagement across multiple states, and an extended cash runway from 2028 out to 2029.
Market Pulse Summary
This announcement highlights early commercialization with limited Q1 2026 revenue of $14,000, disciplined R&D spend of $3.0M, and a net loss of $8.4M. The PRIME trial in 5,018 women and reductions in early preterm births support the PreTRM test’s clinical story. With about $86.8M in cash expected to fund operations through 2029, investors may watch revenue traction, payer adoption, and European CE marking progress.
Key Terms
randomized trial medical
nicu medical
neonatal morbidity medical
ce marking regulatory
AI-generated analysis. Not financial advice.
Key First Quarter and Recent Highlights:
- Published Landmark PRIME Randomized Trial: Study in 5,018 women showing the PreTRM® test reduced early preterm births (–
56% <32 weeks; –32% <35 weeks), NICU admissions (–20% ), and neonatal morbidity (-20% ), with one NICU day saved per 4.2 patients screened. - Expanded European Evidence Base with Two Peer-Reviewed Publications:
- PREPARE Survey Accepted for Publication in The Journal of Women's Health: In March, results from the Pregnancy Research on European Women's Preterm Birth Awareness, Risk and Education (PREPARE) survey were accepted for publication evaluating preterm birth awareness, risk perception, and education across five countries. Findings identified a meaningful gap between perceived awareness and actionable understanding of preterm birth risk, underscoring the need for earlier and more standardized risk communication, an area PreTRM® testing is designed to address. The live publication is expected in May.
- European Expert Commentary on the PRIME Trial Published in The Journal of Maternal-Fetal & Neonatal Medicine: In March, expert commentary highlighted that current European preterm birth prevention strategies fail to identify most women who deliver preterm. They recognized that the PreTRM approach better aligns with existing European healthcare systems.
- Commercial Progress: Launched third partnership program expanding physician education and access to PreTRM. This program is expected to reach over 350 providers across three states. In parallel, we are now engaged in active discussions with 13 payers across 15 states, reflecting our strategy to deepen relationships within a focused set of target markets.
- Strong Presence Across Key Medical Meetings:
- American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting in May: Participation included a dedicated product theater and targeted engagement with clinicians to discuss evidence generation and clinical implementation of PreTRM.
- Society of Maternal-Fetal Medicine (SMFM) Annual Meeting in February: Highlighted key clinical evidence from PRIME study and engaged with maternal-fetal medicine specialists on PreTRM's role in risk stratification and early intervention. We also engaged with SMFM leadership to discuss the PRIME study outcomes.
- Continued Progress in
Europe : Advancing toward CE marking with regulatory dossier preparation on track for mid‑year submission. Commercial readiness efforts are supported by ongoing clinical validation activities and engagement with European clinical and advisory stakeholders. - Cash Runway Extended Through 2029: As part of the final phase of our transition from a clinical to a commercial organization, we completed a comprehensive business review to redirect investment from clinical activities toward commercialization and rightsized our operating model, resulting in a sustainable cost structure to support the company across significant adoption and commercialization milestones through 2029.
"In the first quarter, our primary focus was building awareness with clinicians and the broader stakeholder community as we continue the evolution from clinical stage to a commercial driven organization," said Zhenya Lindgardt, President and CEO of Sera Prognostics. "We made meaningful progress translating our expanding clinical foundation into commercial readiness, supported by growing peer reviewed validation in
"During the quarter, we advanced into the next phase of our evolution as a commercial organization through a comprehensive business review. As discussed in prior quarters, we redirected investment from clinical spend toward reimbursement driven commercialization while maintaining a sustainable cost structure," said Austin Aerts, Chief Financial Officer of Sera Prognostics. "These actions extended our cash runway by approximately one year, through 2029, providing the financial flexibility to fund the company through key adoption and commercial milestones."
Upcoming Investor Conferences
Company management will participate in the following investor conferences. When a fireside chat is scheduled a live webcast will be accessible through the Investors section of the Company's website for approximately 30 days following each conference.
- RBC Capital Markets Global Healthcare Conference May 19-20, 2026 in
New York : Zhenya Lindgardt, President & CEO will host one-on-one meetings on Tuesday, May 19. - Jefferies Global Healthcare Conference June 2-4, 2026 in
New York : Zhenya Lindgardt, President and CEO, and Dr. Tiffany Inglis, Chief Medical Officer, will participate in a fireside chat on Wednesday June 3, at 9:20am ET and host one-on-one meetings. - William Blair 46th Annual Growth Stock Conference June 2-4 in
Chicago : Austin Aerts, Chief Financial Officer, and Jay Boniface, Chief Scientific Officer, will host one-on-one meetings on Wednesday June 3.
First Quarter 2026 Financial Results
First quarter 2026 revenue was
Total operating expenses were
Research and development expenses for the first quarter of 2026 were
Selling, general and administrative expenses for the first quarter of 2026 were
Net loss for the quarter was
As of March 31, 2026, the Company had cash, cash equivalents, and available-for-sale securities of approximately
Conference Call Information
Sera Prognostics will host a corresponding conference call and live webcast today to discuss first quarter 2026 operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing the following:
US domestic callers: (800) 836-8184
International callers: (646) 357-8785
Webcast Registration Link: https://app.webinar.net/voeWlGmwyd6
Live audio of the webcast will be available online from the Investors page of the Company's website at www.sera.com. The webcast will be archived on the Investors page and will be available for one year.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera's precision medicine PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns. The 2025 March of Dimes Report Card shows that, for the fourth consecutive year,
About the PreTRM® Test
The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman's individual risk. The PreTRM® Test is ordered by a medical professional.
Sera, Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the date and time and content of the Company's quarterly earnings release and conference call; availability of the live audio of the conference call on the Company's website; the Company's third partnership program expanding physician education and access to PreTRM and reaching over 350 providers across three states; advancing toward CE marking with regulatory dossier preparation on track for mid‑year submission; a sustainable cost structure and funding the Company across significant adoption and commercialization milestones through 2029; translating the Company's expanding clinical foundation into commercial readiness, increasing clinician engagement, and expanded education and access; scaling in high value markets and driving adoption of the PreTRM® test; extending the Company's cash runway by approximately one year, through 2029; providing the financial flexibility to fund the Company through key adoption and commercial milestones; expected revenue expansion in the future; the Company's attendance at, Company leadership's availability for one-on-one meetings at, and the availability of webcasts from the RBC Capital Markets Global Healthcare Conference May 19-20, 2026 in
Contacts:
Investor Contact
Jennifer Zibuda, Head of Investor Relations
jzibuda@sera.com
+1 (801) 396-8043
Media Contact
Nicole Kaplan at Allison Worldwide
sera@allisonworldwide.com
+1 (847) 721-6033
SERA PROGNOSTICS, INC. | ||||||||
Condensed Statements of Operations | ||||||||
(unaudited) | ||||||||
(in thousands, except share and per share data) | ||||||||
Three Months Ended | ||||||||
March 31, | ||||||||
2026 | 2025 | |||||||
Revenue | $ | 14 | $ | 38 | ||||
Operating expenses: | ||||||||
Cost of revenue | 42 | 40 | ||||||
Research and development | 3,030 | 3,334 | ||||||
Selling and marketing | 2,012 | 1,470 | ||||||
General and administrative | 4,290 | 4,444 | ||||||
Total operating expenses | 9,374 | 9,288 | ||||||
Loss from operations | (9,360) | (9,250) | ||||||
Interest expense | (2) | (4) | ||||||
Other income, net | 963 | 1,067 | ||||||
Net loss | $ | (8,399) | $ | (8,187) | ||||
Net loss per share, basic and diluted | $ | (0.17) | $ | (0.20) | ||||
Weighted-average shares outstanding, basic and diluted | 50,258,849 | 41,968,076 | ||||||
SERA PROGNOSTICS, INC. | ||||||||
Condensed Balance Sheets | ||||||||
(unaudited) | ||||||||
(in thousands) | ||||||||
March 31, | December 31, | |||||||
2026 | 2025 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 4,175 | $ | 3,944 | ||||
Marketable securities | 43,226 | 35,257 | ||||||
Accounts receivable | 11 | 12 | ||||||
Prepaid expenses and other current assets | 2,314 | 1,557 | ||||||
Total current assets | 49,726 | 40,770 | ||||||
Property and equipment, net | 1,096 | 1,149 | ||||||
Long-term marketable securities | 39,365 | 56,579 | ||||||
Intangible assets, net | 881 | 910 | ||||||
Other assets | 2,476 | 2,525 | ||||||
Total assets | $ | 93,544 | $ | 101,933 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 767 | $ | 862 | ||||
Accrued and other current liabilities | 2,342 | 3,009 | ||||||
Finance lease obligation, current portion | — | 2 | ||||||
Deferred revenue | 20,310 | 20,315 | ||||||
Total current liabilities | 23,419 | 24,188 | ||||||
Operating lease obligation, net of current portion | 2,505 | 2,337 | ||||||
Total liabilities | 25,924 | 26,525 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity: | ||||||||
Common stock, Class A and Class B | 4 | 4 | ||||||
Additional paid-in capital | 387,721 | 386,864 | ||||||
Accumulated other comprehensive income | 16 | 262 | ||||||
Accumulated deficit | (320,121) | (311,722) | ||||||
Total stockholders' equity | 67,620 | 75,408 | ||||||
Total liabilities and stockholders' equity | $ | 93,544 | $ | 101,933 | ||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-reports-first-quarter-2026-financial-results-302764424.html
SOURCE Sera Prognostics, Inc.